Consultant in Hematology Mayo Clinic Rochester, MN
Hematology
Dr. Scott H. Kaufmann, MD
|
|
Give Review
Doctor Scott H. Kaufmann, MD practices Hematology. He attended Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is one of the top medical schools in the US. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care Scott Kaufmann is a published doctor. He has 102 publications published. The most current publication "APOBEC3G expression correlates with T cell infiltration and improved clinical outcomes in high-grade serous ovarian carcinoma."
Publications
- Prime, shock, and kill: Priming CD4 T cells from HIV patients with a BCL-2 antagonist before HIV reactivation reduces HIV reservoir size.
- 4EBP1/c-MYC/PUMA and NFκB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.
- Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
- Immunodetection of human topoisomerase I-DNA covalent complexes.
- Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.
- Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells.
- BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.
- Bim regulation miRrors microRNA 17∼92 cluster expression in endothelial cells in vivo.
- COMMD1 is linked to the WASH complex and regulates endosomal trafficking of the copper transporter ATP7A.
- Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation.
- Loss of HSulf-1 expression enhances tumorigenicity by Inhibiting Bim expression in ovarian Cancer.
- APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma.
- Contribution of bcl-2 phosphorylation to bak binding and drug resistance.
- Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
- Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias.
- Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm.
- Enhanced killing of Cancer cells by Poly(ADP-ribose) Polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
- Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.
- A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
- Therapy-related Acute promyelocytic leukemia (t-APL): Observations relating to APL pathogenesis and therapy.
- Multi-institutional Phase II clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed Acute myelogenous leukemia.
- Death receptor 5 signaling promotes hepatocyte lipoapoptosis.
- Isolation of a TRAIL antagonist from the serum of HIV infected patients.
- High cell surface death receptor expression determines type I versus type II signaling.
- Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory Acute leukemia.
- Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization.
- Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.
- Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim upregulation.
- Poly(ADP-ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian Cancer cells.
- Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.
- Drug efflux by breast Cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-5...
- Cancer. Targeting bacteria to improve Cancer therapy.
- Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.
- Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.
- Development of PARP inhibitors: an unfinished story.
- Mcl-1 degradation during hepatocyte lipoapoptosis.
- Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human Acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-53692...
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
- Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice.
- Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis.
- Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant Liver cell lines.
- Active oral regimen for elderly adults with newly diagnosed Acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib...
- Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin.
- Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
- AntiCancer therapy: boosting the bang of Bim.
- Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.
- BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis.
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
- Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I.
- Apoptosis-associated caspase activation assays.
- Dynamics of granzyme B-induced apoptosis: mathematical modeling.
- Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
- Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins.
- Genetic analysis of the short splice variant of the inhibitor of caspase-activated DNase (ICAD-S) in chicken DT40 cells.
- Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1.
- Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity.
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated Acute myelogenous leukemia.
- Synthesis of novel caspase inhibitors for characterization of the active caspase proteome in vitro and in vivo.
- Apoptosis in the treatment of Cancer: a promise kept?
- Imatinib spells BAD news for Bcr/abl-positive Leukemias.
- Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-termin...
- Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.
- Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity.
- Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
- Resistance of Cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochond...
- In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
- Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.
- Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory Acute leukemia.
- Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic ...
- Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
- Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6...
- Heat shock protein 90 inhibition sensitizes Acute myelogenous leukemia cells to cytarabine.
- Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in Acute promyelocytic leukemia.
- Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells.
- A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced Cancer.
- Proteomic analysis of mantle-cell lymphoma by protein microarray.
- The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.
- Gene expression profiles predict early relapse in ovarian Cancer after platinum-paclitaxel chemotherapy.
- Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine.
- A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced Cancer.
- S-peptide epitope tagging for protein purification, expression monitoring, and localization in mammalian cells.
- Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel.
- Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.
- Apoptosis: an optimization approach.
- Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
- Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patie...
- Rad9 protects cells from topoisomerase poison-induced cell death.
- Caspase-7 gene disruption reveals an involvement of the enzyme during the early stages of apoptosis.
- Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human Leukemia cells.
- Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines.
- Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in Acute lymphoc...
- A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced Cancer.
- Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in Cancer.
- Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung Cancer.
- Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.
- A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
- Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism.
- Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.
- Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic Leukemia.
- APOBEC3G expression correlates with T cell infiltration and improved clinical outcomes in high-grade serous ovarian carcinoma.
Schools
Johns Hopkins University School Of Medicine
Johns Hopkins Hospital
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Coagulation Disorders (incl. Hemophilia)
- Hemophilia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
Johns Hopkins University -
Johns Hopkins University School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Helpful Reviews
Similar Doctors
|
|
Dr. Animesh D. Pardanani, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Curtis A. Hanson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexandra P. Wolanskyj, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Denis M. Bonin, MD |
|
|
Dr. Brian J. Davis, MD |
|
|
Dr. Kebede Hussein, MD |
|
|
Dr. Ivy A. Petersen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katharine A. Price, MD
This Doctor is OpenDoctor Recommended.
|